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Abstract
Tumor necrosis factor a (TNF-a) is a key regulator of inflammation and rheumatoid arthritis (RA). TNF-a blocker therapies can
be very effective for a substantial number of patients, but fail to work in one third of patients who show no or minimal
response. It is therefore necessary to discover new molecular intervention points involved in TNF-a blocker treatment of
rheumatoid arthritis patients. We describe a data analysis strategy for predicting gene expression measures that are critical
for rheumatoid arthritis using a combination of comprehensive genotyping, whole blood gene expression profiles and the
component clinical measures of the arthritis Disease Activity Score 28 (DAS28) score. Two separate network ensembles, each
comprised of 1024 networks, were built from molecular measures from subjects before and 14 weeks after treatment with
TNF-a blocker. The network ensemble built from pre-treated data captures TNF-a dependent mechanistic information, while
the ensemble built from data collected under TNF-a blocker treatment captures TNF-a independent mechanisms. In silico
simulations of targeted, personalized perturbations of gene expression measures from both network ensembles identify
transcripts in three broad categories. Firstly, 22 transcripts are identified to have new roles in modulating the DAS28 score;
secondly, there are 6 transcripts that could be alternative targets to TNF-a blocker therapies, including CD86 - a component
of the signaling axis targeted by Abatacept (CTLA4-Ig), and finally, 59 transcripts that are predicted to modulate the count
of tender or swollen joints but not sufficiently enough to have a significant impact on DAS28.
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Introduction
Rheumatoid arthritis (RA) is a common autoimmune disease
that is characterized by inflammation and destruction of the joints
[1]. Inflammation is caused by the infiltration of inflammatory
cells, including neutrophils, macrophages, B- and T-cells into the
normally acellular synovial tissue that lines the junction of bones.
A key feature of the inflammatory process is the release by the
infiltrating cells of proinflammatory cytokines, including TNF-a,
interleukin-1 (IL-1), interleukin-6 (IL-6), and others. These
cytokines promote further inflammation and joint destruction by
activating infiltrating immune cells as well as resident bone cells
and promoting the release of degradative enzymes such as matrix
metalloproteases and cathepsins. Another key feature of the
disease is the presence of autoantibodies directed against
citrullinated proteins and other targets that contribute to joint
damage as well as systemic manifestations of RA [2]. Like other
autoimmune diseases, RA is caused by complex interactions
between genes and environment [3].
RA is treated with small molecule, disease-modifying anti-
rheumatic drugs (DMARDs) including Methotrexate, Sulfasala-
zine, Leflunomide and others [4]. Biologic agents include several
tumor necrosis factor alpha (TNF-a) blockers such as Etanercept,
Infliximab and Adalimumab, co-stimulation blockers (abatacept
or CTLA4-Ig) and B-cell depleters (rituximab). DMARDs are
often combined with tumor necrosis factor alpha (TNF-a)
blockade. For many patients, TNF-a blockade effectively relieves
arthritis symptoms as measured by American College of
Rheumatology (ACR) or Disease Activity Score (DAS) scoring
systems that measure numbers of tender and swollen joints as well
as other clinical parameters. Typically 39% of patients score
better than ACR 50 in etanercept trials when dosed at 10 mg or
25 mg twice weekly, and 64% of patients scored better than ACR
20 [5]. However, for particular subsets of rheumatoid arthritis
patients, TNF-a blockade does not appear to relieve the
symptoms of RA.
A genetic component to RA has been established from twin and
family studies. The estimated heritability of RA is about 60%, and
the genetic basis is complex with consistent association of HLA,
PTPN22, TRAF1-C5, and several other loci [6]. Some of these
genetic variants have also been associated with differential
response to treatment with TNF-a blockers [7]. However,
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variants affect RA phenotypes or differential response to TNF-a
blocker to inform rational selection of molecular intervention
targets for RA remains a challenging problem.
Establishing causal mechanisms, particularly in clinical data, is a
difficult exercise and is often assessed using two popular
approaches [8]. One approach uses probabilistic evidence from
cross-sectional population studies and discovers new stable
statistical associations between the measurements. However,
discovering statistical links between the measurements alone
cannot determine the causal direction. Another uses mechanistic
evidence arising from knowledge of an existing physical property
and establishes a predictable dependency over time. However,
discovering new mechanistic knowledge demands experimentation
and leads directly to the first approach of statistical, probabilistic
analysis of the collected data.
Probabilistic or mechanistic causality models alone appear to be
at once insufficient and irreconcilable. Scientific inferences from
approaches that are unable to effectively reconcile these two
notions of causality typically experience delays in their acceptance.
There have been many instances of strong probabilistic links in
clinical data that have not been accepted until the mechanism had
been discovered. Rigorous clinical science correctly requires that
both probabilistic and mechanistic arguments need to be met
simultaneously before a particular claim can be accepted as causal
[8].
The scientific method provides a framework to address both
aspects of causality simultaneously [8]. First, existing evidence is
used to propose a constrained rational mechanism. Second, controlled
experiments or perturbations are designed to test the mechanism,
and relevant data are collected on the proposed mechanistic
molecules. Finally, an appropriate systematization of the collected
data deduces probabilistic reflections of known mechanisms and infers
new aspects of the mechanism that can be directly tested. If the
inferred aspects are confirmed, the proposed mechanism is
accepted as causal.
To develop a causal data analysis approach to rational drug
target and biomarker discovery in RA, we used published data
from the Autoimmune Biomarkers Collaborative Network (AB-
CoN) [9]. The ABCoN recruited more than 100 patients naı ¨ve to
anti-TNF treatment for systematic clinical and molecular analysis.
Clinical data for calculating Disease Activity Score 28 (DAS28),
and blood samples for genetic (SNP) and expression profiling
analysis, were collected at baseline (pretreatment), as well as 6
weeks and 14 weeks after starting therapy for one of three anti-
TNF molecules (Etanercept, Infliximab or Adalimumab). In our
analysis of ABCoN data, we assume a rational mechanism that
genetic variation arising from meiosis in this study population
together with drug therapy are systematic perturbations that
impact RA through multiple molecular and physiological
interactions that are probabilistically reflected in the blood
transcription profile data. Systematization of the gene expression
and clinical data enable us to distinguish transcripts that play a
role in modulating RA phenotypes from those that are either
simply correlated with or secondary to the phenotypes.
Bayesian networks provide a convenient framework for
systematizing data to deduce probabilistic orderings and modeling
large systems of interacting variables [10,11,12,13,14]. Most
previous studies have concentrated on either estimating the
structural connections in the system under study or on the
identification of disease associated genetic polymorphisms. Simu-
lation of Bayesian networks can be used to predict the effect of
specific interventions. Whereas some previous studies make
predictions based on a single network topology [15,16,17,18,19],
our approach adds to these in two important ways. First it
generates a statistical sample, or ensemble, of network structures
that are consistent with data collected [20,21]. Second, it enables
quantitative prediction of the effects of perturbations [22] that
account for uncertainty about network topology.
With the ability to predict the impact of specific interventions
that were not part of the collected data in defined study subjects,
the ensemble organizes the data into a rational model and also
predicts unseen events. In this regard, these simulation-ready
integrative genomic ensembles capture the essence of the scientific
method described previously.
Here we concentrate on the prediction of gene expression levels
that are critical to explaining the number of swollen joints (SJ), the
number of tender joints (TJ), the amount of pain and the plasma
concentration of C-reactive protein (CRP) in the subjects enrolled
in the ABCoN trial with and without TNF-a blocker treatment.
Sets of biomarkers predictive of TNF-a blocker response have
been identified [23,24]. This should serve as an important
diagnostic tool to help determine who would or would not benefit
from a TNF-a blocker therapy. While there are treatment options
for those who do not respond to TNF-a blocker therapies,
identifying those patients before they begin biologics or early in
their treatment would help rationalize their treatment. Addition-
ally, uncovering molecular alterations underlying TNF-a blocker
response will be critical to discovering new and effective therapies
for RA.
Results
Using ABCoN study data to explore mechanisms of
differential response to TNF-a blockade
While DMARDs, TNF-a blockers and other treatments are
available for RA patients [1,25], there is still a need to identify new
drug targets for patients whose disease does not respond to
available therapies. If the molecular mechanism for TNF-a
blocker failure were understood, the knowledge would allow drug
researchers to more effectively select molecules that could target
this particular subgroup of patients. Simulation-capable ensemble
Author Summary
The collection and analysis of clinical data has played a key
role in providing insights into the diagnosis, prognosis and
treatment of disease. However, it is imperative that
molecular and genetic data also be collected and
integrated into the creation of network models, which
capture underlying mechanisms of disease and can be
interrogated to elucidate previously unknown biology.
Bringing data from the clinic to the bench completes the
cycle of translational research, which we demonstrate with
this work. We built disease models from genetics, whole
blood gene expression profiles and the component clinical
measures of rheumatoid arthritis using a data-driven
approach that leverages supercomputing. Genetic factors
can be utilized as a source of perturbation to the system
such that causal connections between genetics, molecular
entities and clinical outcomes can be inferred. The existing
TNF-a blocker treatments for rheumatoid arthritis are only
effective for approximately 2/3 of the affected population.
We identified novel therapeutic intervention points that
may lead to the development of alternatives to TNF-a
blocker treatments. We believe this approach will provide
improved drug discovery programs, new insights into
disease progression, increased drug efficacy and novel
biomarkers for chronic and complex diseases.
Targets for Rheumatoid Arthritis
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providing clues to the reasons some patients do not respond.
The ideal strategy to learn the probabilistic mechanisms of non-
response would be to integrate circulating drug concentrations
(pharmacokinetic data), measures of the effectiveness of the drug
(pharmacodynamic data), genetic variation, relevant molecular
measures from the disease-affected tissues and finally, components
of DAS28 into a single network ensemble model. Differences in all
these measures would lead to an ensemble model that could
effectively recover TNF-a blockade response in genetically defined
subjects. To recover non-response targets, molecular measures for
non-responding subjects would be set in the ensemble and
systematic in silico perturbations for each non-responding subject
would be completed to give a set of intervention points for these
particular subjects. For alternative targets to TNF-a in non-
responding subjects, the pharmacokinetic variables would be set to
mimic a TNF-a blocker concentration of zero. If the focus were to
find combination therapies, the simulations would be completed
where the pharmacokinetic variables mimicked realistic circulating
doses.
For the ABCoN study, there are no pharmacokinetic or
pharmacodynamic measures, such as phospho-proteomic data
available to enable the modeling strategy outlined. In addition,
and as seen in this data set and other studies [26], TNF-a
transcript levels vary so little in whole blood that they cannot be
considered as a surrogate for pharmacokinetic or pharmacody-
namic measures. This means that the data cannot be used to
effectively understand the probabilistic mechanisms of response, or
non-response, to TNF-a blocker therapy.
However, while a mechanistic analysis is difficult within the
current study design, we can investigate transcription variation
with and without an undefined amount of circulating TNF-a
blocker activity with the expectation that models built using data
collected before TNF-a blocker therapy will be informative for
untreated RA and mainly reflect TNF-a dependent mechanisms.
Additionally, models built using data collected from treated
subjects are expected to reveal aspects of RA that are still
important even after TNF-a signaling has been interdicted.
Critical transcripts identified from the network ensemble built
from data collected after treatment could represent both starting
points for drug target identification for subjects who will not
respond and combination therapy targets that are only important
when TNF-a blocker is circulating in the patient.
Reverse-Engineer and Forward-Simulate (REFS) predictive
framework
Our method works by considering all possible associations
between DNA variation, gene expression, and RA clinical data,
resulting in a collection of network fragments derived from these
measurements and reflecting not only associations between the
traits, but how the different variables are causally associated as
well. Each network fragment defines a quantitative, continuous
relationship among all possible sets of 3 or fewer measured
molecular variables. Because of the experimental design, where
DNA variation is leveraged as the randomization mechanism
needed to make causal inferences, these fragments approximate
stable, probabilistic cause and effect relationships [11]. The
relationship is supported by a Bayesian probabilistic score that
deduces how likely the candidate relationship is given the
measurements and also penalizes the relationship for its mathe-
matical complexity (Figure 1B). By exhaustively scoring all of the
possible pairwise and three-way relationships inferred from the
DNA, expression, and RA clinical data, the most likely fragments
can be identified and held aside preferentially in the collection for
later use. Network fragments that include SNPs are constrained
such that the genotypes are always upstream of gene expression or
clinical outcome data, reflecting the assumption that genotypes are
systematic perturbations to the disease. However, network
fragments that are comprised of gene expression and clinical
outcome data alone could affect each other through multiple
causal mechanisms, and therefore we considered all possible
orderings of three or fewer variables. In addition to assessing the
probability of a particular relationship, the quantitative parame-
ters of the relationship are computed and stored, an important
departure from previous methods that have primarily focused on
structure. Rather than discarding this quantitative information, we
store it so that it can be queried to draw more complex inferences
later on in our process.
In the second phase, we estimate an ensemble of network
models based on data from the integrative genomics experiment.
A statistical definition of the ensemble is a sample of networks
drawn from all possible networks consistent with the data, and
whose properties are robust, regardless of either the actual
structures contained within it or the algorithmic starting conditions
that generated it. Even though a normally distributed random
variable can take on infinitely many values, sampling even as few
as 30 numbers from the distribution can provide reliable estimates
of the mean and standard deviation of the distribution, thereby
perfectly characterizing the behavior of the random variable. In
much the same way, our approach samples from the space of all
possible networks to approximate the distribution of that space,
enabling an effective characterization of that space. In the third
phase we use forward simulation of networks in the ensemble to
generate predictions of the effects of perturbations. The entire
process is summarized in Figure 1. The entire process is repeated
for data collected before and 14 weeks after TNF-a blocker
therapy, giving two distinct network ensembles that capture
untreated and treated aspects of RA mechanism.
Summaries of data processing, diagrams of the consensus
structure of the two models with respect to the DAS28
components (Figure 2) and the mathematical assessment of the
quality of the models generated by the framework are provided
(Table 1 in Text S1 and Figures S1–S3). Briefly, the untreated
network ensemble was built using 6,075 SNPs, which included
imputed genotypes for previously identified SNPs associated with
RA, 4,794 gene expression values and 4 DAS28 component
scores. The treated network ensemble was built using 6,076 SNPs,
4,512 gene expression values and 4 DAS28 component scores.
The network sample properties were assessed by completing three
independent network sampling procedures using different, random
starting conditions. There were no significant differences in the
sample properties regardless of the starting conditions demon-
strating that the sampling procedure had converged. The
predictive properties of the network sample were assessed using
simulations designed to measure how accurate the network
ensemble recovered the actual observed data (Text S1).
Model intervention simulations – Virtual clinical trials
Systematic in silico simulations of 10-fold knockdown of all 9,306
transcripts were completed to provide quantitative predictions of
how modulation of a particular gene expression measure would
affect the DAS28 score in every particular subject given their own,
individualized genotype and gene expression values before and
after treatment with TNF-a blocker. Simulated distributions of SJ,
TJ, Pain and CRP were compiled from 30 replicate gene
expression simulations for each subject and for each gene. A
single predicted DAS28 component score for each individual
patient was then estimated as the median of the 30 replicate
Targets for Rheumatoid Arthritis
PLoS Computational Biology | www.ploscompbiol.org 3 March 2011 | Volume 7 | Issue 3 | e1001105Figure 1. Schematic of Bayesian network reverse engineering and Monte Carlo simulation. A. Genetic, gene expression and phenotypic
data are prepared for modeling by formatting followed by investigation to select the appropriate data transformation for the particular data type.
Confounding factors and other explanatory variables are considered and modeled if appropriate. B. Likely fragments for network reconstruction are
identified by scoring all 2-, 3- and 4-variable combinations with the constraint that SNPs are causally upstream. There are too many scored
combinations to consider all during network reconstruction. The fragments that had the most likely Bayesian scores for each individual variable were
identified and retained for network reconstruction. C. Parallel global network sampling constructs an ensemble of 1024 network structures that
explain the data. The probabilistic directionality computed by the Bayesian framework allows inferences to be made about what lies upstream and
downstream of particular phenotypic variables D. Diversity in network structures identified during network reconstruction captures uncertainty in the
model. Hypotheses are extracted from the network ensemble by completing Monte Carlo simulations of ‘‘what-if’’ scenarios. Down-regulating the
blue transcript would be expected to impact both TJ and SJ, while leaving CRP unchanged. The change in these phenotypic parameters would
further predict reactive transcription changes in the liver. The separation of upstream and downstream components can identify potential
intervention points and markers.
doi:10.1371/journal.pcbi.1001105.g001
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predicted values. The simulated and summarized SJ, TJ, Pain and
CRP scores were used to estimate a simulated DAS28 score using
the standard equation supplied to clinicians.
Gene expression perturbations were ranked by their ability to
sufficiently modulate RA clinical measures in a significant number
of patients using either a x
2 test for TJ and SJ scores or a Student’s
t-test for Pain and CRP with respect to simulated untreated gene
expression DAS28 scores.
Identification of three classes of causal transcripts
78 transcripts from the untreated network ensemble (see Table
S1) and 97 transcripts from the TNF-a blocker treated network
ensemble (see Table S2) were predicted to significantly modulate
Figure2.Consensustopologyofnetworkensembles forpre-treatedandTNF-ablockertreateddata.A.Snapshot ofthenetworkensemble
at2.5%consensustopologygeneratedfrompre-treatedsubjects.Paindoes not appear tobecontrolledbymeasuresextractedfromwholebloodmRNA
profiling in pre-treated subjects. B. Snapshot of the network consensus topology at 2.5% consensus generated from TNF-a blocker treated data.
doi:10.1371/journal.pcbi.1001105.g002
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identified can be assigned to one of three broad categories based
on their predicted efficacies and druggability, which was assessed
using Ingenuity Pathway Analysis (Ingenuity Systems, www.
ingenuity.com). Category 1 transcripts are defined as transcripts
that have a predicted novel role in RA (Tables 1 and 2), are not
directly related to TNF-a biology and have statistically significant
impacts on DAS28 and joint health. Category 2 transcripts are
potential alternatives to TNF-a therapies and have known
dependencies on TNF-a or are proteins that could be targeted
with a small molecule and are predicted to modulate DAS28 and
joint health (Tables 3 and 4). Category 3 transcripts are those that
are predicted to impact joint health but not DAS28 across the
subjects simulated (Tables 5 and 6).
Literature analysis of REFS identified intervention points
Intervention points identified by REFS were analyzed to
identify significantly enriched biological process using the GOstats
package from R/Bioconductor, an open source software for
bioinformatics [27,28]. Molecular processes associated with
nuclear factor kappa-B (NF-kappa-B) were identified from the
pretreatment gene list (Table 7). NF-kappa-B is a family of
transcription factors that are induced by TNF-a and other stimuli,
and are critically important for inflammatory processes [29].
Genes associated with myeloid cell differentiation are also
enriched in the untreated samples. Myeloid cells, including
neutrophils, monocytes and macrophages, are producers of
TNF-a. These cells also express TNF receptors, and on
stimulation with TNF-a can produce even more of this cytokine
as well as other pro-inflammatory molecules [30]. Terms relating
to T helper cell differentiation and IL-4 biosynthesis were also
among the significantly enriched molecular processes for tran-
scripts identified as important for RA under TNF-a blocker
therapy (Table 8), perhaps reflecting T-cell related pathways as
well as B-cell activations and affecting RA while TNF-a signaling
is therapeutically suppressed.
Network analysis predicts LASS5 and IL32 as TNF-a
dependent causal factors for swollen joint count
LASS5, longevity assurance homolog 5, is identified as a
modulator for number of swollen joints. It is a ceramide synthase
that synthesizes ceramide de novo. It has been shown that
overgrowth of rheumatoid synoviocytes leads to joint destruction,
and ceramide regulates cell growth by inhibiting pro-survival
signals such as those from AKT, MEK and ERK [31]. Ceramide is
also known as a pro-inflammatory signaling molecule and may
regulate several matrix metalloproteases that can degrade cartilage
tissue [32,33].
Simulation results suggest that LASS5 expression interacts with
the expression of interleukin 32 (IL32) to modulate the number of
swollen joints (Figure 3–4). In silico perturbations of IL32 are
predicted to affect number of swollen joints. IL32 is a cytokine
induced by TNF-a and may play a critical role in rheumatoid
arthritis. Injection of human IL-32 protein into knee joints of mice
Table 1. Category 1 Transcripts from the post-treatment model.
Gene Symbol Name TJ SJ DAS28
RAP2C RAP2C, member of RAS oncogene family X X X
ANXA1 Annexin A1 XX X
GON4L gon-4-like (C. elegans) X X X
CPVL carboxypeptidase, vitellogenic-like X X X
SMARCD2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d,
member 2
XX X
SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 X X X
EID1 EP300 interacting inhibitor of differentiation 1 X X X
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) X X X
EIF3D eukaryotic translation initiation factor 3, subunit D X X
CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 X X
NDE1 nudE nuclear distribution gene E homolog 1 (A. nidulans) X X
NCOA1 nuclear receptor coactivator 1 X X
ARHGAP25 Rho GTPase activating protein 25 X X
MBP Myelin basic protein X X
JMJD3 jumonji domain containing 3 X X
In Tables 1 and 2, these transcripts have a predicted novel role in either untreated or treated RA, are not directly related to TNFa biology and have statistically significant
impacts on DAS28 or joint health (denoted by X, p,0.05).
doi:10.1371/journal.pcbi.1001105.t001
Table 2. Category 1 Transcripts from the pre-treatment
model.
Gene Symbol Name TJ SJ DAS28
DOK3 Docking protein 3 X X
C15orf39 Chromosome 15 orf 39 X X
FLOT2 Flotillin 2 X X
RHOG Ras homolog gene family, member G
(rhoG)
XX
NBPF1 neuroblastoma breakpoint family,
member 1
XX
GLT1D1 glycosyltransferase 1 domain containing 1 X X
FLJ43663 hypothetical protein FLJ43663 X X
doi:10.1371/journal.pcbi.1001105.t002
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damage and this effect is dependent on the presence of TNF-a
[34]. The predicted effect of IL32 is not detected in the network
ensemble built from data from TNF-a blocker treated subjects,
agreeing with experimental data and further suggesting that the
treated network ensemble is capturing TNF-a independent
mechanisms in RA.
Network analysis predicts WARS as a TNF-a dependent
causal factor for tender joint count
Persistence of autoimmune activated T-cells is a feature of RA
[35]. Typically, T-cells can be suppressed by indoleamine 2,3-
doxygenase (IDO) signaling which triggers the catabolism of
tryptophan and subsequent suppression of T-cell response [36].
WARS is a tryptophanyl-tRNA synthetase whose gene expression
is significantly elevated in T-cells derived from the synovial fluid of
RA patients and leads directly to the sequestration of intra-cellular
tryptophan in the form of tryptophanyl-tRNA. With intra-cellular
stores of free tryptophan lowered by over-expression of WARS,
IDO signaling is now muted and can explain the persistence of
activated T-cells in RA patients and their resistance to IDO [37].
Simulations suggest that knockdown of WARS gene expression can
significantly affect the number of tender joints sufficiently and
strongly enough to modulate DAS28.
WARS gene expression is predicted to be a modulator of RA
only in pretreated subjects, suggesting that WARS mechanism is
TNF-a dependent (Figure 5). This assertion is confirmed because
enhanced gene expression of WARS that leads to tryptophan
sequestration is dependent on TNF-a in experimental systems
[37].
CD86 is a predicted to be a TNF-a independent causal
factor for joint health
CD86 (B7-2) is identified as a strong modulator of TJ, SJ and
DAS28 in the network analysis of TNF-a blocker treated patients
and should represent a particular TNF-a independent mechanism
that is active in RA patients (Figure 6).
CD86 is a type I membrane protein expressed by antigen-
presenting cells (APC) and is the ligand for CD28 and CTLA4 on
the surface of T-cells. Binding of this ligand to CD28 or CTLA4
provides co-stimulatory signals that can either positively or
negatively regulate T-cell activation that are independent of
TNF-a.
Abatacept (CTLA4-Ig) is an approved biologic drug that
exploits this mechanism by blocking the co-stimulatory signal
from CD80/CD86 thus preventing the full activation of T-cells
[38]. The drug is approved for patients that have shown
unsatisfactory response to TNF-a blocker drugs, clearly demon-
strating that network reconstruction and simulation of data
collected under TNF-a blocker treatment recovers TNF-a
independent mechanisms that could be used to identify drug
targets for the segment of the population that does not respond to
TNF-a blocker therapy.
RAP2C and GON4L are novel predicted TNF-a
independent causal factors for TJ and SJ
In silico perturbations further identified RAP2C (Figure 7) and
GON4L (Figure 8) as causal factors for TJ, SJ and DAS28 score.
Very little is currently known about either of these transcripts and
this is the first analysis that suggests a role for these transcripts as
TNF-a independent modulators of joint health in RA patients.
RAP2C is a novel member of Ras G-protein family and the
model predicts that perturbation of RAP2C leads to significant
changes of TJ, SJ and DAS28 score.
GON4L is a human ortholog of the Caenorhabditis elegans cell
lineage regulator of gonadogenesis GON4L. This gene is a putative
transcription factor that may regulate cell cycle control. GON4L
has been shown to be an essential regulator of B-cell development
[39]. Notably, B-cells are the target for rituximab, a monoclonal
antibody against CD20 that is approved for the treatment of RA
patients with insufficient response to TNF-a blockade [40]. B cells
produce IL-6 upon activation, and IL-6 blocking molecules have
also been approved for RA treatment [41]. Our analysis suggests
that GON4L may be a novel target for RA by modulating B-cell
differentiation.
Discussion
It is important to recognize that the network ensembles are built
from gene expression profiles of whole blood and are not directly
measured from diseased tissue in the joints, which complicates the
assessment of the transcripts identified as outright targets in RA.
Additionally, mRNA from whole blood had to be depleted of
hemoglobin mRNA and the resulting subtracted mRNA sample
was amplified using specialized PCR fluorescence labeling
protocols that may introduce bias in the measurements. The
unavoidable technical details meant that collected data were noisy
and there was a large amount of network structure diversity
recovered in the ensemble sample after network reconstruction.
However, the predicted magnitude of the effects of some of the
Table 3. Category 2 Transcripts from the post-treatment model.
Gene Symbol Name TJ SJ DAS28
TRAF3IP3 TRAF3 interacting protein 3 X X
PSMD4 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 X X
CD86 CD86 molecule X X X
In Tables 3 and 4, transcripts are potential alternatives to TNF-a therapies and have known dependencies on TNF-a or are proteins that could be targeted with a small
molecule and their predicted modulation might be expected to modulate DAS28 or joint health (p,0.05).
doi:10.1371/journal.pcbi.1001105.t003
Table 4. Category 2 Transcripts from the pre-treatment
model.
Gene Symbol Name TJ SJ DAS28
WARS tryptophanyl-tRNA synthetase X X
LASS5 LAG1 homolog, ceramide synthase 5 X X
CTSC Cathepsin C X X
doi:10.1371/journal.pcbi.1001105.t004
Targets for Rheumatoid Arthritis
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despite the uncertainty in the network ensemble. Furthermore,
when interpreting inferences from the network ensemble it is
important to recognize that there could be hidden common or
intermediate causes that were not part of the measured dataset
that could modify the logic of the causal inferences encoded in the
ensemble.
The transcripts identified using network simulations represent
quantitative hypotheses about control points in untreated and
TNF-a blocker treated RA patients. The promise of this approach
is exemplified by the recognition of the T cell co-stimulatory
molecule CD86 and the B-cell restricted molecule GON4L in the
TNF-a blocker treated samples. The network simulations were
based purely on the data and did not include any up-front
literature information or supervision. The models suggest that
modulation of these molecules would impact disease scores, and
these molecules represent previously validated pathways for
treating patients with insufficient response to TNF-a blockade.
Not every intervention point identified by the models will be as
clear as CD86, and the genes we identify should be considered as
starting points in the investigation of a wider range of pathway and
signaling mechanisms that have not been widely examined for
therapeutic benefit. For example, the therapeutic potential of a
systematic WARS inhibitor is questionable but other molecular
components of IDO signaling might present better therapeutic
potential.
Table 5. Category 3 Transcripts from the post-treatment model.
Gene Symbol Name TJ SJ DAS28
1558906_a_at NA XX
MGST3 microsomal glutathione S-transferase 3 X
FLJ22662 hypothetical protein FLJ22662 X X
LANCL1 LanC lantibiotic synthetase component C-like 1 (bacterial) X
SFRS18 splicing factor, arginine/serine-rich 18 X X
KPNB1 karyopherin (importin) beta 1 X X
EXOSC6 exosome component 6 X
RAD23A RAD23 homolog A (S. cerevisiae) X
DPYD dihydropyrimidine dehydrogenase X X
FUSIP1 FUS interacting protein (serine/arginine-rich) 1 X X
WIPF2 WAS/WASL interacting protein family, member 2 X X
CFLAR CASP8 and FADD-like apoptosis regulator X
HNRPA3P1 heterogeneous nuclear ribonucleoprotein A3 pseudogene 1 X
INHBC inhibin, beta C X X
COX18 COX18 cytochrome c oxidase assembly homolog (S. cerevisiae) X
FGL2 fibrinogen-like 2 X
GSTO1 glutathione S-transferase omega 1 X
FLJ43663 hypothetical protein FLJ43663 X
TNRC6B trinucleotide repeat containing 6B X
EIF3F eukaryotic translation initiation factor 3, subunit F X
MBNL1 muscleblind-like (Drosophila) X
SUB1 SUB1 homolog (S. cerevisiae) X
PRDM2 PR domain containing 2, with ZNF domain X
C10orf46 chromosome 10 open reading frame 46 X
CENTB2 centaurin, beta 2 X
LRRFIP2 leucine rich repeat (in FLII) interacting protein 2 X
DOCK8 dedicator of cytokinesis 8 X
TMEM14C transmembrane protein 14C X
OSGEP O-sialoglycoprotein endopeptidase X
ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 X
LOC727918 hypothetical protein LOC727918 X
RPS2 ribosomal protein S2 X
VAPA VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa X
RNF6 ring finger protein (C3H2C3 type) 6 X
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 X
EXT1 exostoses (multiple) 1 X
In Tables 5 and 6, transcripts are predicted to impact joint health (p,0.05) but not DAS28 (p.0.05).
doi:10.1371/journal.pcbi.1001105.t005
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PLoS Computational Biology | www.ploscompbiol.org 8 March 2011 | Volume 7 | Issue 3 | e1001105Rheumatoid Arthritis drugs recommended by The American
College of Rheumatology (ACR) fall into several categories: small
molecule DMARDs including methotrexate, lefluonamide and
others; anti-TNF-a agents; T-cell activation modulators; IL-6
antagonists; IL-1 antagonists; and B-cell directed therapy. The
analysis conducted in this study is relevant for all of these
therapeutic approaches, but ideally suited for identifying new
pathways to target in patients with insufficient response to first-line
DMARDS and biologics such as anti-TNFs. Whereas the
DMARDS have relatively broad mechanisms of action impacting
several inflammatory pathways, the biologics all have very targeted
mechanisms and are generally used only after DMARDS have
failed. While the pleiotropic effects of the biologics overlap, each
class of biologics targets a specific feature of inflammation. The
anti-TNFs are by far the most common, and these target
inflammatory processes driven by macrophages that are close to
the top of the inflammatory cascade. In current practice, other
biologics are used primarily after DMARDS and anti-TNFs fail.
Table 6. Category 3 Transcripts from the pre-treatment model.
Gene Symbol Name TJ SJ DAS28
PITPNA phosphatidylinositol transfer protein, alpha X
N4BP1 Nedd4 binding protein 1 X
XPO6 exportin 6 X
IMPDH1 IMP (inosine monophosphate) dehydrogenase 1 X
HLA-E major histocompatibility complex, class I, E X
DPYSL2 dihydropyrimidinase-like 2 X
LRP10 low density lipoprotein receptor-related protein 10 X
EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 X
RALY RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow
homolog (mouse))
X
NT5C2 59-nucleotidase, cytosolic II X
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional
peptidase 2)
X
STAT3 signal transducer and activator of transcription 3 (acute-phase response factor) X
FNBP1 formin binding protein 1 X
IL32 interleukin 32 X
TRBC1 T-cell receptor beta constant 1 X
PCSK7 proprotein convertase subtilisin/kexin type 7 X
SSH2 slingshot homolog 2 (Drosophila) X
MAPKAP1 mitogen-activated protein kinase associated protein 1 X
LAMP2 lysosomal-associated membrane protein 2 X
PCGF3 polycomb group ring finger 3 X
RUNX1 runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) X
NFIL3 nuclear factor, interleukin 3 regulated X
CFLAR CASP8 and FADD-like apoptosis regulator X
Transcripts predicted to impact joint health (p,0.05) but not DAS28 (p.0.05)
doi:10.1371/journal.pcbi.1001105.t006
Table 7. Significantly enriched immune response related GO terms for transcripts from untreated model.
GOBPID Pvalue Count Size Term
GO:0045639 0.000201651 2 5 positive regulation of myeloid cell differentiation
GO:0006955 0.002364924 10 778 immune response
GO:0045637 0.002648076 2 17 regulation of myeloid cell differentiation
GO:0030097 0.008668954 3 93 hemopoiesis
GO:0006436 0.009086186 1 2 tryptophanyl-tRNA aminoacylation
GO:0042386 0.035861484 1 8 hemocyte differentiation (sensu Arthropoda)
GO:0000086 0.044627838 1 10 G2/M transition of mitotic cell cycle
GO:0042345 0.048981641 1 11 regulation of NF-kappaB import into nucleus
GO:0043123 0.049036663 2 78 positive regulation of I-kappaB kinase/NF-kappaB cascade
doi:10.1371/journal.pcbi.1001105.t007
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have a track record and there are several to choose from – but may
also reflect underlying disease heterogeneity. The network analysis
supports the notion that underlying disease heterogeneity is
important. Different biological pathways are active with and
without anti-TNF-a treatment. Furthermore, T-cell and B-cell
pathways targeted by approved RA drugs clearly emerge from the
model as reflected by the impact of modulating CD86, part of the
abatacept (CTLA4-Ig) target, and GON4L, expressed in B cells
that are the target of rituximab (anti-CD20).
Candidate targets identified by network analysis can be put into
specific inflammatory pathways. While the pathways have been
previously identified, some of the specific transcripts have not been
recognized as being associated with RA before. These newly
identified transcripts highlight pathways for small-molecule or
biologic treatments of RA. In addition to the few genes mentioned
above, network analysis predicts additional transcripts such as
STAT3. STAT3 has been identified as a pro-survival molecule for
RA synoviocytes [42], and has also been shown to mediate some of
the pro-inflammatory signaling of IL-6 {Hirano, #88} – yet
another target of approved RA treatments. Additionally,
FLJ43663 is predicted to be a secreted protein and represents a
novel type of molecule identified through network simulation.
Of the eighteen genes significantly affecting counts of Swollen
Joints (SJ), correlative statistical models identified only two
transcripts, CTSC and IL32. REFS identified the importance of
RUNX1, a transcription factor that regulates genes such as BLK,
TCR, CD3 and GM-CSF in lymphoid cells [44] and which may
play a role in autoimmune disease such as rheumatoid arthritis
[45]. REFS ranked RUNX1 as the fifth most important transcript
modulating SJ while correlative statistical models ranked RUNX1
as the 1280
th most important transcript (See Figure S4A). Further
investigation of the REFS network model suggests that RUNX1
affects SJ by modulating hypothetical gene FLJ43663. In this
manner, REFS identified a completely novel intervention point
and provided insight into its potential mechanism (See Figure
S4B).
Network models that incorporate genetic, molecular, and
clinical data collected from longitudinal samples represent a
powerful complement to classical statistical models for identifying
genes and pathways important for disease processes. We
developed ensemble models for a small cohort of RA patients
sampled prior to and during treatment with TNF-a blockers.
These ensemble models accurately predict the involvement of
known RA drug targets including T cell co-stimulation and B cell
regulation. These observations suggest that other genes and
pathways identified in the network ensembles represent promising
targets for further investigation.
Methods
Processing and imputation of genotyping data
The Illumina HAP300 chip was used to profile the genotypes of
patients. The most recent genomic coordinates for human SNPs
were downloaded from the Ensembl website. The updated
genomic positions were used together with MACH [46], a
Markov-chain haplotyper to impute missing genotypes from the
data as well as previously identified SNPs associated with RA.
HLA types were mapped to SNP positions based on HLA-SNP
map [47]. All genotypes from the X and Y chromosome were
removed from consideration because the analysis of hemizygous
genotypes produces false positive associations. SNPs that failed
Hardy-Weinberg equilibrium test, or had a minor allele frequency
(MAF) (p,0.05), or had a call-rate,95% were also removed. The
SNP QC process resulted in 279,557 SNPs selected for further
analysis and the process is detailed in Table 2 in Text S1.
EIGENSTRAT was used to detect and correct for population
stratification on a genome-wide scale that was detected in the full
data set using smartPCA. The associated Armitage chi-squared
statistic is computed for each SNP and used to rank SNPs
associated with phenotypes to produce a ranked list of SNPs that
were potentially important in explaining RA treated and untreated
phenotypes. 6,075 SNPs and 6,076 SNPs were chosen from the
ranked lists to model untreated and treated subjects respectively.
Assessment and processing of gene expression data
Simpleaffy was used to assess the quality of microarray
hybridization [48]. The majority of samples lay within the tolerances
suggested by Affymetrix for amplified RNA samples. The entire
microarray data set was normalized using FARMS [49]. This
normalization technique has outperformed previously developed
methods in the Affycomp II competition [50] in detecting differential
gene expression and is used in conjunction with an associated package
called I/NI (Informative/Non-Informative) that uses variance across
the dataset to identify informative genes for further analysis [51].
Assessment and processing of DAS28 data
All subjects in the data had DAS28 scores for all visits and the
components of the DAS28 score were also available. Pair plots of
the components of the DAS28 scores show that the components
themselves are orthogonal to each other and capture different
aspects of RA. Visual analogue scale for overall health assessment
Table 8. Significantly enriched immune response related GO terms for transcripts from anti-TNF-a treated model.
GOBPID Pvalue Count Size Term
GO:0045064 0.010795911 1 2 T-helper 2 cell differentiation
GO:0042097 0.010795911 1 2 interleukin-4 biosynthesis
GO:0042109 0.010795911 1 2 tumor necrosis factor-beta biosynthesis
GO:0045624 0.016150771 1 3 positive regulation of T-helper cell differentiation
GO:0030154 0.025370559 7 537 cell differentiation
GO:0042092 0.02677505 1 5 T-helper 2 type immune response
GO:0042093 0.02677505 1 5 T-helper cell differentiation
GO:0045086 0.032044769 1 6 positive regulation of interleukin-2 biosynthesis
GO:0045621 0.037286403 1 7 positive regulation of lymphocyte differentiation
doi:10.1371/journal.pcbi.1001105.t008
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PLoS Computational Biology | www.ploscompbiol.org 10 March 2011 | Volume 7 | Issue 3 | e1001105Figure 3. 10-fold knockdown of IL32 modulates number of swollen joints. Plots of simulated number of tender joints, swollen joints, pain
and C-reactive protein concentrations in response to a 10-fold knockdown in gene expression of cytokine IL32 in A. pretreated subjects and B. TNF-a
blocker treated subjects. The effects are only predicted in pre-treated patients, suggesting a dependence on TNF-a signaling. The largest predicted
effect is to modulate the number of swollen joints.
doi:10.1371/journal.pcbi.1001105.g003
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PLoS Computational Biology | www.ploscompbiol.org 11 March 2011 | Volume 7 | Issue 3 | e1001105Figure 4. Swollen joints predicted to be modulated by LASS5 in pre-treated patients only. Plots of simulated number of tender joints,
swollen joints, pain and C-reactive protein concentrations in response to a 10-fold knockdown in gene expression of ceramide synthase, LASS5,i nA .
pretreated subjects and B. TNF-a blocker treated subjects. The modulation of swollen joints is only predicted in pre-treated patients, suggesting a
dependence on TNF-a signaling.
doi:10.1371/journal.pcbi.1001105.g004
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PLoS Computational Biology | www.ploscompbiol.org 12 March 2011 | Volume 7 | Issue 3 | e1001105Figure 5. Tender joints predicted to be modulated by WARS in pre-treated patients only. Plots of simulated number of tender joints,
swollen joints, pain and C-reactive protein concentrations in response to a 10-fold knockdown in gene expression of tryptophanyl-tRNA synthetase,
WARS, in A. pretreated subjects and B. TNF-a blocker treated subjects. The modulation of tender joints is only predicted in pre-treated patients,
suggesting a dependence on TNF-a signaling.
doi:10.1371/journal.pcbi.1001105.g005
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PLoS Computational Biology | www.ploscompbiol.org 13 March 2011 | Volume 7 | Issue 3 | e1001105Figure 6. Modulation CD86 predicted to affect both tender and swollen joint counts in TNF-a treated patients. Plots of simulated
number of tender joints, swollen joints, pain and C-reactive protein concentrations in response to a 10-fold knockdown in gene expression of CD86,
the target of abatacept (CTLA4-Ig), in A. pretreated subjects and B. TNF-a blocker treated subjects. The modulation of tender joints is only predicted
in TNF-a treated patients, suggesting both a mechanism that is independent of TNF-a signaling that could be exploited for subjects that do not
respond well to TNF-a blocker therapies.
doi:10.1371/journal.pcbi.1001105.g006
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PLoS Computational Biology | www.ploscompbiol.org 14 March 2011 | Volume 7 | Issue 3 | e1001105Figure 7. RAP2C predicted to modulate both tender and swollen joint counts in TNF-a treated patients. Plots of simulated number of
tender joints, swollen joints, pain and C-reactive protein concentrations in response to a 10-fold knockdown in gene expression of RAP2C, a recently
described ras G-protein, in A. pretreated subjects and B. TNF-a blocker treated subjects. The simulations suggest that this novel gene can modulate
both tender and swollen joint count in TNF-a treated subjects. RAP2C may provide insight into novel TNF-a independent signaling pathways in RA.
doi:10.1371/journal.pcbi.1001105.g007
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PLoS Computational Biology | www.ploscompbiol.org 15 March 2011 | Volume 7 | Issue 3 | e1001105Figure 8. GON4L predicted modulate both tender and swollen joint count in TNF-a treated patients. Plots of simulated number of tender
joints, swollen joints, pain and C-reactive protein concentrations in response to a 10-fold knockdown in gene expression of GON4L, recently described
as a novel factor in B-cell differentiation, in A. pretreated subjects and B. TNF-a blocker treated subjects. The simulations suggest that this novel gene
can modulate both tender and swollen joint count in TNF-a treated subjects. GON4L may provide insight into novel TNF-a independent signaling
pathways in RA.
doi:10.1371/journal.pcbi.1001105.g008
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PLoS Computational Biology | www.ploscompbiol.org 16 March 2011 | Volume 7 | Issue 3 | e1001105scores and the health assessment questionnaire showed a high
degree of correlation with the pain score component of the DAS28
and were considered redundant.
Tender joint count (TJ), Swollen joint count (SJ) and Pain scores
were logit transformed with an additional discrete to continuous
continuity correction applied prior to REFS modeling. C-reactive
protein concentrations (CRP) were log transformed prior to analysis
to ensure valid, non-zero simulation results in response to
intervention queries and to stabilize the variance across the data set.
Learning probabilistic models from data
A multivariate system with random variables X=(X 1,… ,X n)
where each variable may take on values from a discrete (genetic
markers) or continuous domain (gene expression and phenotypic
data) may be characterized probabilistically by a joint multivariate
probability distribution function P(X1,… ,X n; H). However, full
specification of such joint probability distributions requires a large
number of parameters H. Such a global joint probability
distribution admits the following factorization into a product of
local conditional probability distributions:
P(X1,:::,Xn;H)~ P
n
i~1
Pi(XijYj1,:::,YjKi;Hi) ð1Þ
where each variable Xi is independent of its nondescendants given
its Ki parents Yj1,… ,Y jKi (local Markov condition) and Hi are
parameters for Pi. The Y variables are simply a subset of the X’s;
we use the Y notation to indicate they are inputs to the conditional
probability. This approach yields a framework where each
particular factorization and choice of parameters is a distinct
probabilistic model M of the structure of the process that created
the observed data [11]. Learning these models M from a data set D
is simply determining which factorizations of P(X1,… ,X n;H) are
most likely given the observation of D, and given a factorization,
what are the likely values for its parameters H=(H1,… ,Hn).
Each factorization of P(X1,… ,X n) into model M (as in Eq. 1) is
represented by a unique Directed Acyclic Graph (DAG) G with a
vertex for each Xi and directed edges between vertices to represent
the dependencies between variables embedded in the local
conditional distributions, Pi(Xi|Yj1,… ,Y jKi). In addition to the
graph G, M also specifies distributions for all Hi the parameters of
local conditional distributions Pi. Subgraphs of G, consisting of a
vertex and a set of all its incoming edges, and associated local
conditional distributions Pi and parameters Hi, are referred to here
as ‘‘network fragments’’. We interpret each of these network
fragments Mi to characterize both the functional variation of its
output variable Xi with respect to its parent input variables Yj1,… ,
YjKi and the residual variation in Xi. For integrative genomics we
consider several specific functional forms for network fragments
and used linear regression. First, consider the case where all of the
input variables Yj1,… ,Y jKi are continuous, then we model the
centroid of Xi by:
^ X Xi~h0zhj1Yj1z:::zhjKiYjKi ð2Þ
and Xi by a normal distribution about that value:
XieN(^ X Xi,s2
i ) ð3Þ
The parameters si, h0, hj1,… ,hjKi can be thought of as adjusted to
best fit the data inthe Maximum Likelihood Estimation (MLE)sense.
The likelihood function gives the posterior distribution of the
parameter values about the MLE point. Next, consider the case
where one of the Y variables is discrete. To model its influence its
linear term in Eq. 2 is dropped and the discrete value is used to switch
the value of the remaining linear fitting parameters. That is to say, for
each value of the discrete variable a different set h0, hj1, …, hjKi of fitting
parameters is introduced. Finally, if multiple Y’s are discrete all of
their linear terms are dropped from Eq. 2 and their joint discrete state
is used as the switching value. In this study all of the output variables
Xi are continuous: discrete variables are only taken as inputs.
Parallel ensemble sampling
To determine which factorizations are likely given the data we
use a Bayesian framework to compute the posterior probability of
the model P(M|D) from Bayes’ Law
P(MjD)~
P(DjM)P(M)
P(D)
ð4Þ
where P(D) is the probability of D, P(M) is the prior probability of
the model and
P(DjM)~
ð
P(DjM(H))P(HjM)dH ð5Þ
is the integral of the data likelihood over the prior distribution of
parameters H. We assume that data is complete. Assuming that
parameters H are independent, all models are equally likely, and
P(D) is constant, we factor P(M|D) in Eq. 4 into the product of
integrals over the parameters local to each network fragment Mi.
Eq. 4 now becomes
P(DjM)~ P
n
i~1
ð
P(DjMi(Hi))P(HijMi)dHi ð6Þ
where P(Hi |Mi) is the network specific prior for its parameters.
For this work we use Schwartz’s Bayesian Information Criterion
approximation to the above integral (asymptotically exact as the
number of samples increases):
S(Mi)~{log
ð
P(DjMi(Hi))P(HijMi)dHi&SBIC(Mi)
~SMLE(Mi)z
k(Mi)
2
logN
ð7Þ
where k(Mi) is the number of fitting parameters in model Mi and N
is the number of samples. We refer to S as a ‘‘score’’, but note the
minus sign in the definition (to agree with the simulated annealing
analogy described below) and so lower scores are more likely. SMLE
is the negative logarithm of the MLE value of the likelihood
function.
The total network score is:
{log(P(DjM))~Stot(M)~
X n
i~1
S(Mi) ð8Þ
a sum over the scores of each network fragment in the candidate
graph model. In principal the repository of candidate network
fragments can be constructed by exhaustive enumeration over
variables and network fragment forms. We selected models that
provided highest likelihood [52,53] and considering at most 2
edges for a particular vertex. However, even with these
constraints, the space of all possible graphs is still too large to be
sampled by exhaustive enumeration.
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PLoS Computational Biology | www.ploscompbiol.org 17 March 2011 | Volume 7 | Issue 3 | e1001105Instead we use the Metropolis method (Markov Chain Monte
Carlo) to generate samples from an equilibrium Boltzmann
distribution of candidate structures [54] from P(M|D). Each step
in a Metropolis Markov Chain corresponds to local transfor-
mations such as adding or deleting network fragments. To
accelerate convergence we used simulating annealing were we
applied the Metropolis method to a sequence of distributions
exp({Stot(M)=Tj) with decreasing Tj (annealing temperature).
At each stage j the equilibrated samples from Tj initialize the
Metropolis method at Tj+1. Convergence of the random walk is
monitored along the way and the annealing schedule is dynamically
modified to take more Monte Carlo steps when the barriers present
a larger obstacle to diffusion through the space of networks. The
method for doing this was to estimate rate of change with respect to
T of the mean total score SStotT and also its variance
SS2
totT{SStotT
2 (the angle brackets denote Monte Carlo averages
over networks at the current T.) From these values the change in
temperature, T’{T~DT, is selected so that the distribution of Stot
at T’ will have 80% overlap with the distribution at T. This process
ofmaintainingoverlaphelpsensurethat the samplingwill becorrect
when T=1is reached. In addition, shorter runs were performed to
confirm that results are consistent with the longer runs.
In the normal usage of simulated annealing to find a global
optimum, the control parameter T is allowed to go below 1; as long
as better solutions are still being found the temperature is allowed to
decrease. In our approach we stop at T=1because the sampling
there corresponds directly to the posterior distribution P(M|D) in
Eq. 4; going to lower values of T would lead to over fitting the data.
Model intervention simulations
Stochastic simulation of a probabilistic model M allows
predictions about the distribution of a variable Xi to be made
under different conditions. The conditions can be interventions
with variables in the model and/or different values of inputs to the
model. We used Gibbs sampling in which each variable Xi is
sampled from its conditional Gaussian distribution, such as Eq. 2,
3, whose parameters take on most likely values given data D. For
simulation of subjects not seen in the training data, only roots of
the graph G had values. A simulation routine iteratively sweeps the
network and generates samples of variables whose parents have
already acquired a value in previous iterations until all variables
have values. One full sweep produces one sample (one vector of
values of all variables). Interventions such as a knockdown of gene
transcript expression level variables are done by removal of the
network fragment from M that outputs to the variable and the
network is swept as described previously.
For each subject in the data analysis, the contribution of each
gene simulation was assessed conditioned by the genotype and the
other gene expression measures of the subject.
Supporting Information
Figure S1 Predicted phenotypic values of training data for
untreated model. Plot of simulated data for phenotypes (number of
tender joints, number of swollen joints, pain score, and CRP levels)
based on untreated model vs. observed values. Dashed line
represents the line of unity (y=x) and each circle represents a
patient in the training data. Correlation coefficients (r) for each
phenotype are printed as part of the title.
Found at: doi:10.1371/journal.pcbi.1001105.s001 (0.75 MB EPS)
Figure S2 Predicted phenotypic values of training data for
treated model. Plot of simulated data for phenotypes (number of
tender joints, number of swollen joints, pain score, and CRP levels)
based on treated model vs. observed values. Dashed line represents
the line of unity (y=x) and each circle represents a patient in the
training data. Correlation coefficients (r) for each phenotype are
printed as part of the title.
Found at: doi:10.1371/journal.pcbi.1001105.s002 (0.74 MB EPS)
Figure S3 Predicted phenotypic values of test data. Plot of
simulated data for phenotypes (number of tender joints, number
of swollen joints, pain score, and CRP levels) based on treated
model vs. observed values. Dashed line represents the line of
unity (y=x) and each circle represents a patient in the test data.
Correlation coefficients (r) for each phenotype are printed as part
of the title.
Found at: doi:10.1371/journal.pcbi.1001105.s003 (0.74 MB EPS)
Figure S4 Comparison of REFS with statistical models &
Network topology of example gene. A. Comparison of genes
identified by REFS
TM and correlative statistical models for swollen
joint (SJ) counts of untreated data. B. A Schematic representation
of genes upstream of SJ from untreated model.
Found at: doi:10.1371/journal.pcbi.1001105.s004 (3.03 MB EPS)
Table S1 Significant transcripts identified from untreated
network ensemble. Transcripts from the untreated network
ensemble were predicted to significantly modulate any of the
DAS28 component scores (p,0.05).
Found at: doi:10.1371/journal.pcbi.1001105.s005 (0.03 MB XLS)
Table S2 Significant transcripts identified from the TNF-a
blocker treated network ensemble. Transcripts from theTNF-a
blocker treated network ensemble were predicted to significantly
modulate any of the DAS28 component scores (p,0.05).
Found at: doi:10.1371/journal.pcbi.1001105.s006 (0.03 MB XLS)
Text S1 Assessment of the accuracy of the network Ensemble.
Found at: doi:10.1371/journal.pcbi.1001105.s007 (0.06 MB
DOC)
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